Search Results 461-470 of 16654 for pharmacogenetics
The purpose of this study is to evaluate the real-world utilization of ceftolozane/tazobactam (C/T) and to assess patient outcomes. Participation eligibility.
Aim 1: To determine the metabolic effects of decreasing circulating EOS in healthy subjects. Mepolizumab is an FDA-approved drug that selectively reduces ...
ROCHESTER, Minn. — At Mayo Clinic, cardiologists Peter Noseworthy, M.D., and John Giudicessi, M.D., Ph.D., are uncovering the earliest signs of a genetic heart ...
ROCHESTER, Minn. — A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for[...] ...
Review the student roster and career outcomes of the Predoctoral Training Program in Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic.
Rochester, Minn. The purpose of this study is to attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
PHOENIX — Current genetic screening guidelines fail to identify most people with an inherited condition known as familial hypercholesterolemia that can ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift can go 3X as far to shape the future of cancer care.